ClinicalTrials.gg
RecruitingNCT07378527Updated Apr 21, 2026

Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

A Phase 2/3 interventional study of ICP-332 Tablets and ICP-332 placebo Tablets in Chronic Spontaneous Urticaria (CSU), sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 30 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Chronic Urticaria with a site in China — 16 open to participants now, 20 under way, 5 of them phase 3. Chronic Urticaria · China.

Planned enrollment
7th of 30
344 · median 110
Started
2026
with 10 others
Phase 2/3
2 of 34
1 open now
Primary completion
2028-09
later than 19 of 19 live
Registered
23rd of 34
by date
Lead sponsor
1 of 34
Beijing InnoCare Pharma Tech Co., Ltd.

Among the 34 studies in Chronic Urticaria with a site in China, this one is the 7th largest by planned enrollment of the 30 interventional ones that give a count, is one of 11 that started in 2026, is one of 2 in phase 2/3, reaches primary completion later than 19 of the 19 other live ones, and was the 23rd registered.

Chronic Urticaria

197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

16 of the 34 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Chronic Urticaria with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines

03

Conditions studied

  • Chronic Spontaneous Urticaria (CSU)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Men and women aged 18 to 75 years.
  • 2. Diagnosis of CSU inadequately controlled by second generation H1-antihistamines.
  • 3. CSU duration for ≥ 6 months prior to randomization.
  • 4. Before initiating any screening or study-specific procedures, the subject must voluntarily sign the form.

Exclusion criteria

Exclusion Criteria:

  • 1. Having the other medical conditions related to CSU or other skin diseases/conditions.
  • 2. Potential medical conditions or issues.
  • 3. Pregnant female subjects or lactating female subjects.
  • 4. The investigator determines that the subject is unsuitable for participating in this study for any reason.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
344 participants (estimated)

Study arms

  • Experimental
    ICP-332 dose A(Phase2)

    ICP-332 will be administered as tablet

    Drug: ICP-332 Tablets

  • Experimental
    ICP-332 dose B(Phase2)

    ICP-332 will be administered as tablet

    Drug: ICP-332 Tablets

  • Experimental
    ICP-332 dose C(Phase2)

    ICP-332 will be administered as tablet

    Drug: ICP-332 Tablets

  • Placebo comparator
    Placebo(Phase2)

    ICP-332 Placebo will be administered as tablet

    Drug: ICP-332 placebo Tablets

  • Experimental
    ICP-332 dose A or dose B or dose C(Phase3)

    ICP-332 will be administered as tablet

    Drug: ICP-332 Tablets

  • Placebo comparator
    Placebo(Phase3)

    ICP-332 Placebo will be administered as tablet

    Drug: ICP-332 placebo Tablets

Interventions

  • ICP-332 will be administered as tablet for 12 weeks

  • DrugICP-332 placebo Tablets

    ICP-332 placebo will be administered as tablet for 12 weeks

  • ICP-332 will be administered as tablet for 24 weeks

06

What researchers measure

Primary outcomes

  1. Phase 2: Change from baseline in Weekly Urticaria Activity Score (UAS7) at Week 4.

    The Weekly Urticaria Activity Score (UAS7) is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42 (highest urticaria severity), and a minimum possible score of 0.

    Time frame: 4 weeks

  2. Phase 3: Change from baseline in UAS7 at Week 12.

    The Weekly Urticaria Activity Score (UAS7) is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).

    Time frame: 12 weeks

07

Study locations

1 of 30 sites recruiting
  • Bengbu Medical University First Affiliated Hospital
    Bengbu, Anhui 233004, China
    Not yet recruiting
    • Congjun Jiang · Contact
  • The Second Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui 241000, China
    Not yet recruiting
    • Ruzhi Zhang · Contact
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
    Recruiting
    • Jianzhong Zhang · Contact
    • Cheng Zhou · Contact
  • Beijing Tongren Hospital, Capital Medical University
    Beijing, Beijing Municipality 100730, China
    Not yet recruiting
    • Aihua Wei · Contact
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400016, China
    Not yet recruiting
    • Tao Cai · Contact
  • Chongqing Traditional Chinese Medicine Hospital
    Chongqing, Chongqing Municipality 400021, China
    Not yet recruiting
    • Qingchun Diao · Contact
  • First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
    Not yet recruiting
    • Niu Xiang · Contact
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong 510091, China
    Not yet recruiting
    • Bin Yang · Contact
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Not yet recruiting
    • Xiaoguang Zhang · Contact
  • The Second Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan, China
    Not yet recruiting
    • Bin Zhang · Contact
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
    Not yet recruiting
    • Hongwei Liu · Contact
  • Jingzhou Central Hospital
    Jingzhou, Hubei 434020, China
    Not yet recruiting
    • Yi Sun · Contact
  • Shiyan Taihe Hospital
    Shiyan, Hubei 442000, China
    Not yet recruiting
    • Haixia Jing · Contact
  • Xiangya hospital central south university
    Changsha, Hunan 410008, China
    Not yet recruiting
    • Juan Su · Contact
  • Suzhou Municipal Hospital
    Suzhou, Jiangsu 215002, China
    Not yet recruiting
    • Jun Gu · Contact
  • Wuxi No. 2 People's Hospital
    Wuxi, Jiangsu 214001, China
    Not yet recruiting
    • Xiaohong Zhu · Contact
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 210031, China
    Not yet recruiting
    • Hui Xu · Contact
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
    Not yet recruiting
    • Shan shan Li · Contact
  • Shenyang Hospital of Integrated Traditional Chinese and Western Medicine (Shenyang Seventh People's Hospital)
    Shenyang, Liaoning 110001, China
    Not yet recruiting
    • Zhen Wang · Contact
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
    Not yet recruiting
    • Yan Zheng · Contact
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
    Not yet recruiting
  • Shandong Provincial Hospital for Skin Disease, Shandong First Medical University
    Jinan, Shandong 250022, China
    Not yet recruiting
    • Furen Zhang · Contact
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai Municipality 200443, China
    Not yet recruiting
    • Yangfeng Ding · Contact
  • First Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030001, China
    Not yet recruiting
    • Shuping Guo · Contact
  • Chengdu Second People's Hospital
    Chengdu, Sichuan 610017, China
    Not yet recruiting
    • bin Yin · Contact
  • Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
    Not yet recruiting
    • Min Zhou · Contact
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
    Tianjin, Tianjin Municipality 300131, China
    Not yet recruiting
    • Litao Zhang · Contact
    • Yan Xu · Contact
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
    Not yet recruiting
    • Xiang Nong · Contact
  • Hangzhou Third People's Hospital
    Hangzhou, Zhejiang 310009, China
    Not yet recruiting
    • Xingang Wu · Contact
  • Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
    Hangzhou, Zhejiang, China
    Not yet recruiting
    • Liming Wu · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Sep 2028, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Jan 30, 2026
StartActual
Feb 13, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07378527
Responsible party
Sponsor
First posted
Jan 30, 2026
Start date
Feb 13, 2026
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Apr 21, 2026

Study contacts

Jianzhong Zhang
Contact
rmzjz@126.com
+86-010-88325474

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ICP-332

Start the discussion